Bristol-Myers Squibb Co. (NYSE: BMY) has experienced a rise in its stock price by 0.08 compared to its previous closing price of 53.18. However, the company has seen a gain of 1.95% in its stock price over the last five trading days. benzinga.com reported 2024-10-17 that HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Is It Worth Investing in Bristol-Myers Squibb Co. (NYSE: BMY) Right Now?
Additionally, the 36-month beta value for BMY is 0.45. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 11 rating it as “hold,” and 2 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMY is 2.03B and currently, short sellers hold a 0.99% ratio of that float. The average trading volume of BMY on October 21, 2024 was 12.86M shares.
BMY’s Market Performance
The stock of Bristol-Myers Squibb Co. (BMY) has seen a 1.95% increase in the past week, with a 8.57% rise in the past month, and a 24.72% gain in the past quarter. The volatility ratio for the week is 2.18%, and the volatility levels for the past 30 days are at 2.27% for BMY. The simple moving average for the last 20 days is 1.66% for BMY’s stock, with a simple moving average of 11.26% for the last 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Bernstein repeating the rating for BMY by listing it as a “Mkt Perform.” The predicted price for BMY in the upcoming period, according to Bernstein is $56 based on the research report published on October 17, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see BMY reach a price target of $41. The rating they have provided for BMY stocks is “Equal Weight” according to the report published on July 29th, 2024.
BMY Trading at 5.82% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.59% of loss for the given period.
Volatility was left at 2.27%, however, over the last 30 days, the volatility rate increased by 2.18%, as shares surge +7.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.60% upper at present.
During the last 5 trading sessions, BMY rose by +1.95%, which changed the moving average for the period of 200-days by +1.76% in comparison to the 20-day moving average, which settled at $52.35. In addition, Bristol-Myers Squibb Co. saw 3.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $49.78 back on Dec 05 ’23. After this action, BOERNER CHRISTOPHER S. now owns 82,672 shares of Bristol-Myers Squibb Co., valued at $99,560 using the latest closing price.
BOERNER CHRISTOPHER S., the Chief Executive Officer of Bristol-Myers Squibb Co., purchase 3,071 shares at $48.86 during a trade that took place back on Nov 28 ’23, which means that BOERNER CHRISTOPHER S. is holding 79,384 shares at $150,049 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.71 for the gross margin
The net margin for Bristol-Myers Squibb Co. stands at -0.14. The total capital return value is set at 0.17. Equity return is now at value -26.70, with -6.95 for asset returns.
Based on Bristol-Myers Squibb Co. (BMY), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 3.09. The interest coverage ratio of the stock is 8.01.
Currently, EBITDA for the company is 19.18 billion with net debt to EBITDA at 2.66. When we switch over and look at the enterprise to sales, we see a ratio of 3.35. The receivables turnover for the company is 3.07for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
In conclusion, Bristol-Myers Squibb Co. (BMY) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
